Sangamo Therapeutics Inc is at the forefront of genomic medicine, working to develop transformative treatments for serious diseases. With a focus on gene therapy, cell therapy, and genome editing, the company's pipeline includes potential therapies for Fabry disease, hemophilia A, sickle cell disease, and prevention of kidney transplant rejection. Based in Brisbane, California, Sangamo is collaborating with leading biopharmaceutical companies to advance its clinical trials and preclinical research, aiming to change the lives of patients and families affected by genetic diseases.